Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Solid Tumor
Interventions: BIOLOGICAL: ISU104|DRUG: Cetuximab
Sponsor: ISU Abxis Co., Ltd.